Previously, tiragolumab received breakthrough therapy designation from the FDA with atezolizumab in the first-line treatment of patients with metastatic highly expressing PD-L1 NSCLC whose tumors do not harbor any EGFR or ALK aberrations. This evidence concerns the gene CD274 and non-small cell lung carcinoma.